ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Gut microbiota metabolic axis dysfunction in estrogen deficient stressed rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Resistant Starch Supplementation Modulates Gut Microbiota, Short-Chain Fatty Acids, and Markers of Gut Barrier Integrity in Estrogen-Deficient Mice.Current developments in nutrition · 2026Article
- Fructooligosaccharide supplementation ameliorates gut associated metabolic dysregulation in estrogen-deprived rats via targeting oxidative stress, inflammation, apoptosis, and gut microbiome.Scientific reports · 2026Article
- Gut Microbiota Has the Potential to Improve Sarcopenic Obesity in Menopausal Women by Regulating Estrogen.International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gut dysbiosis, an imbalance in the gut microbiota (GM), has emerged as a key factor contributing to metabolic dysfunction following estrogen deficiency in menopause. Disruptions in gut microbial composition, triggered by hormonal imbalances and chronic stress, can exacerbate metabolic disturbances, such as obesity, dyslipidemia, and diabetes etc. Thus strategies, which modulates gut dysbiosis may proves important for the treatment of metabolic dysfunctions in postmenopausal state. However, the physiological, biochemical and molecular changes occurring due to estrogen deficiency and stress are yet to be elucidated. Thus, aim of the present study was to develop a pre-clinical model to investigate the effect of estrogen deficiency and chronic unpredictable mild stress (CUMS) alone and in combination on GM alterations and associated metabolic dysfunction. Ovariectomized (OVX) rats were subjected to CUMS for 28 days to induce metabolic alterations and gut dysbiosis. Estrogen deficiency and chronic stress altered physiological changes, adiposity, and anthropometric markers. Furthermore, OVX and CUMS elevated oxidative stress in liver and colon and increased inflammatory markers as detected in serum, Liver, and colon. This, in turn, led to damage of the mucosal layer and disruption of tight junction proteins. OVX and CUMS also caused gut dysbiosis, as indicated by an increased ratio of pathogenic to beneficial gut bacterial populations. Histopathological examination showed colon and liver tissues damage in OVX, CUMS, and OVX + CUMS group rats. OVX and CUMS, both individually and synergistically, contributed to the development of gut and metabolic dysfunction, collectively referred to as gut-metabolic axis dysfunction in OVX-stressed rats.
Indexed as
Identifiers
40705081What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.